Cambridge, MA – H3 Biomedicine Inc.,a cancer drug discovery company, unveiled its first phase of growth with the dedication and official opening of new headquarters and 24,000sf of laboratory space in Cambridge.
Over the next year, the company plans to increase its staff to 70 people and further expand into more laboratory space within its building as it continues to pursue its mission to fulfill the promise of personalized cancer medicine.
“H3 Biomedicine is well equipped with our new Cambridge facilities to address some of the most challenging cancers by delivering on our scientific vision of patient-based, genomics-driven drug discovery,” said Markus Warmuth, M.D., H3 Biomedicine
President and CEO.
H3 Biomedicine’s scientific vision was established by scientific founders Dr. Stuart
Schreiber and Dr. Todd Golub of the Broad Institute of Harvard and MIT.
photo in gmail
Caption: Massachusetts Life Sciences Center ViP for Communications Angus McQuilken joins officials from H3 Biomedicine and Eisai to dedicate H3’s new headquarters and lab facilities.
————————————————